During my time at Illumina I had a realisation: restricted access to data, and an industry-wide aversion to collaboration, was delaying and in some instances preventing the discovery of tre
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh